Next Generation Testosterone Assay offers clinically relevant results at Low Concentrations

Abbott has launched a next generation testosterone assay offering improved sensitivity and clinical utility. The ARCHITECT 2nd Generation Testosterone Assay is a cost-effective and convenient chemiluminescent microparticle immunoassay designed to accurately measure the wide range of testosterone levels seen across different patient populations and clinical settings.  

Traditional immunoassay techniques for the clinical determination of testosterone in serum or plasma are not sensitive enough to measure low levels of testosterone for women or children, creating the demand for a convenient and inexpensive alternative to time-consuming chromatographic separation or gold standard LC-MS/MS measurements. The ARCHITECT 2nd Generation Testosterone Assay has been designed specifically to address this need, while also offering clinical utility in the normal male reference range.  

Dr Rien Blankenstein, Professor and Chairman of the Department of Clinical Chemistry at VU University Medical Center, Amsterdam, commented: “Our recent hands-on experience with the ARCHITECT 2nd Generation Testosterone Assay indicates that it allows reliable and reproducible assessment of testosterone in patients suspected to have low circulating testosterone levels. This may be beneficial for patients and their doctors, as well as for the laboratory.”